PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
March 12, 2026Journal of Clinical Oncology0 citationsOpen Access

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

View Full Paper
SHSara A. HurvitzRLRachel M. LaymanGCGiuseppe Curigliano

Key Points

  • This trial aims to evaluate the effectiveness of gedatolisib combined with fulvestrant in advanced breast cancer patients.
  • Phase trial design
  • Investigates the combination of gedatolisib and fulvestrant
  • Includes an evaluation with or without palbociclib
  • Population comprises patients with hormone receptor-positive, HER2-negative, PIK3CA wild-type advanced breast cancer
  • Gedatolisib plus fulvestrant significantly decreased the risk of disease progression or death.
  • The outcomes were better regardless of whether palbociclib was included.

Abstract

The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor-positive/HER2-, PIK3CA WT advanced breast cancer.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Hurvitz et al. (2026) studied this question.

synapsesocial.com/papers/69b25b5496eeacc4fceca00ahttps://doi.org/10.1200/jco-25-02643
Ask AI
Helpful
Bookmark
Share
View Full Paper